104 related articles for article (PubMed ID: 10975710)
1. Elevated levels of opioid growth factor in the plasma of patients with pancreatic cancer.
Smith JP; Conter RL; Demers TM; McLaughlin PJ; Zagon IS
Pancreas; 2000 Aug; 21(2):158-64. PubMed ID: 10975710
[TBL] [Abstract][Full Text] [Related]
2. Opioid growth factor (OGF) inhibits human pancreatic cancer transplanted into nude mice.
Zagon IS; Hytrek SD; Smith JP; McLaughlin PJ
Cancer Lett; 1997 Jan; 112(2):167-75. PubMed ID: 9066724
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of opioid growth factor receptor in human pancreatic adenocarcinoma.
Zagon IS; Smith JP; Conter R; McLaughlin PJ
Int J Mol Med; 2000 Jan; 5(1):77-84. PubMed ID: 10601579
[TBL] [Abstract][Full Text] [Related]
4. Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers.
Zagon IS; McLaughlin PJ
Int J Oncol; 2006 Aug; 29(2):489-94. PubMed ID: 16820893
[TBL] [Abstract][Full Text] [Related]
5. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
[TBL] [Abstract][Full Text] [Related]
6. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells.
Zagon IS; McLaughlin PJ
Int J Oncol; 2004 Jun; 24(6):1443-8. PubMed ID: 15138586
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic cytokines in the sera of patients with pancreatic cancer.
Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Jurkowska G
Clin Chem Lab Med; 2005; 43(2):146-50. PubMed ID: 15843207
[TBL] [Abstract][Full Text] [Related]
8. Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor.
Zagon IS; Smith JP; McLaughlin PJ
Int J Oncol; 1999 Mar; 14(3):577-84. PubMed ID: 10024694
[TBL] [Abstract][Full Text] [Related]
9. Opioid growth factor regulates the cell cycle of human neoplasias.
Zagon IS; Roesener CD; Verderame MF; Ohlsson-Wilhelm BM; Levin RJ; McLaughlin PJ
Int J Oncol; 2000 Nov; 17(5):1053-61. PubMed ID: 11029512
[TBL] [Abstract][Full Text] [Related]
10. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
Ludwig MD; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
[TBL] [Abstract][Full Text] [Related]
11. Opioid growth factor ([Met5]enkephalin) prevents the incidence and retards the growth of human colon cancer.
Zagon IS; Hytrek SD; Lang CM; Smith JP; McGarrity TJ; Wu Y; McLaughlin PJ
Am J Physiol; 1996 Sep; 271(3 Pt 2):R780-6. PubMed ID: 8853403
[TBL] [Abstract][Full Text] [Related]
12. Featured Article: Serum [Met
Ludwig MD; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2017 Sep; 242(15):1524-1533. PubMed ID: 28766982
[TBL] [Abstract][Full Text] [Related]
13. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
[TBL] [Abstract][Full Text] [Related]
14. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
Tsavaris N; Kosmas C; Papadoniou N; Kopterides P; Tsigritis K; Dokou A; Sarantonis J; Skopelitis H; Tzivras M; Gennatas K; Polyzos A; Papastratis G; Karatzas G; Papalambros A
J Chemother; 2009 Dec; 21(6):673-80. PubMed ID: 20071292
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma.
Nazli O; Bozdag AD; Tansug T; Kir R; Kaymak E
Hepatogastroenterology; 2000; 47(36):1750-2. PubMed ID: 11149048
[TBL] [Abstract][Full Text] [Related]
16. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer.
Ventrucci M; Cipolla A; Racchini C; Casadei R; Simoni P; Gullo L
Dig Dis Sci; 2004 Aug; 49(7-8):1149-55. PubMed ID: 15387337
[TBL] [Abstract][Full Text] [Related]
17. Elevated levels of CA 19-9 and CEA in pancreatic cancer-associated diabetes.
Guo Q; Kang M; Zhang B; Chen Y; Dong X; Wu Y
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1627-31. PubMed ID: 20174821
[TBL] [Abstract][Full Text] [Related]
18. Sensitive serum markers for detecting pancreatic cancer.
Hayakawa T; Kondo T; Shibata T; Hamano H; Kitagawa M; Sakai Y; Ono H
Cancer; 1988 May; 61(9):1827-31. PubMed ID: 2451556
[TBL] [Abstract][Full Text] [Related]
19. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
20. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma.
Xu HX; Li S; Wu CT; Qi ZH; Wang WQ; Jin W; Gao HL; Zhang SR; Xu JZ; Liu C; Long J; Xu J; Ni QX; Yu XJ; Liu L
Pancreatology; 2018 Sep; 18(6):671-677. PubMed ID: 30153903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
